Osteosarcoma is the most common malignancy of bone that affects young people.
Neoadjuvant chemotherapy and surgery have significantly improved the prognosis.
However, the prognosis of non-responders to chemotherapy is still poor. To develop peptide-based immunotherapy for osteosarcoma, we previously identified CTL epitopes derived from papillomavirus binding factor (PBF) in the context of human leukocyte antigen (HLA)-A2, HLA-A24 and HLA-B55. In the present study, we identified two novel CTL epitopes, QVT (QVTVWLLEQK) and LSA (LSALPPPLHK), in the context of HLA-A11 using a sequence of screenings based on the predicted affinity of peptides, in vitro folding ability of peptide/HLA-A11 complex, reactivity of peptide/HLA-A11 tetramer and interferon (IFN)-γ production of T cells that was induced by mixed lymphocyte peptide culture under a limiting dilution condition. CTL clones directed to QVT and LSA peptides showed specific cytotoxicity against HLA-
A11
+ PBF + osteosarcoma (HOS-A11) cells. In contrast, another epitope, ASV (ASVLSRRLGK), could highly induce cognate tetramer-positive CTL. This might be because the ASV peptide mimics the peptide ASV (R6Q) (ASVLSQRLGK) derived from bacterial polypeptides, ROK family proteins. However, ASV-induced CTL did not show cytokine production against the cognate peptide. In conclusion, the CTL epitopes QVT and LSA peptides might be useful for the development of immunotherapy targeting PBF for patients with osteosarcoma.
K E Y W O R D S
CTL epitope, in vitro folding ability, MHC-tetramer, osteosarcoma, PBF therapy. 4 To develop T cell-mediated immunotherapies for osteosarcoma, we previously identified papillomavirus binding factor (PBF)
as an osteosarcoma-associated antigen recognized by an autologous CTL clone in the context of human leukocyte antigen (HLA)-B55. 5 Immunohistochemical analysis showed that 92% of biopsy specimens of osteosarcoma expressed PBF. Moreover, PBF-positive osteosarcoma had a significantly poorer prognosis than that with negative expression of PBF. 6 So far, CTL epitopes restricted by HLA-A24 and HLA-A2 have been identified by a reverse immunology approach and tetramer-based frequency analysis. 6, 7 Previous studies on CTL epitopes derived from tumor-associated antigens (TAA) mostly focused on HLA-A2 and HLA-A24 alleles because of the higher worldwide frequency of these alleles. However, HLA-A11 is also present at a high frequency in worldwide popula- In the present study, we aimed to identify novel HLA-A*11:01-restricted CTL epitopes derived from PBF using a sequence of screenings based on the predicted affinity of peptides, in vitro folding ability of peptide/HLA-A11 complex, reactivity of peptide/HLA-A11 tetramer and production of interferon (IFN)-γ of T cells induced by mixed lymphocyte peptide culture under a limiting dilution condition. We also aimed to determine whether CTL clones reacting with each of the PBF peptides recognized naturally presented peptides on osteosarcoma cells.
| MATERIAL S AND ME THODS
The present study was carried out in accordance with the guidelines established by the Declaration of Helsinki and was approved by the institutional review board of Medical & Biological Laboratories Co., Ltd and Sapporo Medical University. Healthy donors provided informed consent for the use of blood samples in our research.
| Donors and cells
Peripheral blood samples were obtained from 5 HLA-A*11:01-positive healthy donors. DNA typing of the HLA-A loci was carried out by the PCR-SSOP-Luminex method using Genosearch HLA-A (MBL, Nagoya, Japan for HLA-A*11:01, followed by selection using G418 (200 μg/mL).
The stable transfectant was designated as HOS-A11. All cell culture reagents were purchased from Sigma-Aldrich (Tokyo, Japan) unless otherwise specified.
| Design and synthesis of PBF-derived peptides
Amino acid sequences of the PBF protein were screened with the HLA-peptide binding prediction software of NetMHC 3.4 (http:// www.cbs.dtu.dk/services/NetMHC/) for oligomeric peptides potentially capable of binding to HLA-A11 molecules. 8 Nine candidate peptides with high scores were selected (Table 1) . They were synthesized using automated solid phase techniques and purified by reversed-phase HPLC, and their sequences were verified by mass spectrometry. The HLA-A*11:01-binding peptide ATVQGQNLK derived from CMV pp65 protein and the HLA-A*24:02-binding peptide AYACNTSTL derived from survivin-2B were also synthesized and used as controls. 9 All peptides were obtained in lyophilized form, dissolved in DMSO at a concentration of 20 mg/mL, and stored in aliquots at −30°C until use. A stock solution of 1 mg/mL was prepared by further dilution in RPMI1640. The first three letters of the peptide sequences are used as shorthand identification throughout the article.
| In vitro folding of peptide-MHC complexes
As described previously, 10,11 the HLA-A*11:01 heavy chain and β2- Pharmaceutical Co., Osaka, Japan) was added to each well, and the medium was replaced every 2 or 3 days thereafter with a fresh me- 
| Major histocompatibility complex-tetramer production and staining
Peptide/MHC tetramers (MHC-tetramers) were produced as described previously. 10 Briefly, recombinant β2m and the extracel- 
| Intracellular IFN-γ staining
Intracellular cytokine staining was done as previously described with some modifications. 13 
| Cytotoxicity assay
Cytotoxicity of tetramer-positive CTL clones was measured by (Table 1) . Next, we investigated whether these potential peptides could form pMHC complexes by using a newly developed in vitro folding system. For in vitro folding, we expressed HLA-A*11:01 in E. coli, dissolved the inclusion bodies in urea buffer, and folded the denatured protein with human β2m and with each peptide.
We then determined the binding ability of the peptide by measuring an amount of pMHC complex with a gel-filtration HPLC assay.
In order to determine the utility of our folding system, a set of molecules showed no obvious change in the peak areas regardless of the incubation period ( Figure 1A ). Because a larger pMHC complex peak indicates better peptide-MHC binding ability, the results indicate that our system is useful for determining the ability of potential peptides to bind to HLA-A*11:01 molecules. In vitro folding ability of these peptides was also correlated with the prediction score of NetMHC 3.4 (Table S1 , Data S1).
For potential peptides of PBF, in vitro folding of each peptide was carried out as described above. All nine peptides that folded with HLA-A*11:01 molecules showed a substantial increase in pMHC complex peaks along with incubation time as well as the positive control peptide ( Figure 1B , Table 1 ). Quantified peak areas are shown in F I G U R E 2 Peak areas of peptide/MHC complexes at different time periods. The peak areas were calculated from the absorption wavelength at 280 nm on day 1 (in white), day 3 (in gray), and day 7 (in black)
| Identification of immunogenic CTL epitopes using a peptide/HLA-A11 tetramer
To determine whether these potential peptides can activate specific CD8 + T cells in vitro, PBF-specific CTL were induced by mixed lymphocyte peptide culture (MLPC) under a limiting dilution condition.
Fourteen days after peptide stimulation, cells were stained with a tetramer that was prepared from the cognate peptide. To set up a more rapid assay system for screening of CTL epitopes, we used three to five potential peptides as a peptide mixture to stimulate PBMC in the presence of IL-2 and autologous plasma but without additional antigenpresenting cells. After MLPC, the cells were stained with tetramers as follows: In the first step, an aliquot of cells from each of the eight wells in a column of a 96-well plate was pooled to make 12 pools (columns 1-12). Then, these samples were stained separately with mixed cognate tetramers. In the second step, pools yielding antigen-specific CTL were further tested for binding of mixed tetramers to cells from individual wells that contributed to the positive pool. In the third step, samples from positive wells were separately stained with individual tetramers to determine which peptide was the specific CTL epitope.
As shown in Figure 3 , three peptides (QVA, LSA and SLP) were used for MLPC in Donors A, B and C. In the first step, 12 pools (columns 1-12) were stained with mixed tetramers (QVA-tet, LSA-tet and SLP-tet). A positive pool with 0.51% tetramer-positive cells was detected in column 10 of Donor C ( Figure 3A ). In the second step, mixed tetramer-positive cells were detected in G well (10-G well) ( Figure 3B ). In the third step, tetramer-positive cells were detected by LSA-tet but not by QVA-tet or SLP-tet ( Figure 3C ).
Next, five peptides (QVA, QVT, KVL, SSL and SLP) were used for MLPC in Donors D and E. As shown in Figure 4A , mixed tetramerpositive cells were detected in two pools (column 7 and column 2 in Donor D and Donor E, respectively) in the first step. Two mixedtetramer-positive wells were detectable in 7-B and in 2-C wells in Donor D and Donor E, respectively, in the second step ( Figure 4B ).
Only QVT-tet-positive cells were detected in both 7-B and 2-C wells in the third step ( Figure 4C ).
We then carried out MLPC using a mixture of three peptides (ASV,
QVT and SAL). In contrast, a high percentage of tetramer-positive cells (up to 38% of CD8 + cells) was detected in all columns of Donors
A, B and C ( Figure 5A ). We tested the reactivity of each tetramer of column 7 in Donor A, column 4 in Donor B and column 4 in Donor C.
As shown in Figure 5B , ASV-tet-positive cells were observed, suggesting that the ASV peptide might be a highly immunogenic CTL epitope.
We also tested another mixture (SVL, KVL and SSL). SVL-tetpositive cells were detected in Donors A, B and C (Figure 6 ), suggesting that immunogenic CTL epitopes derived from PBF in the context of HLA-A*11:01 might be LSA, QVT, ASV and SVL (Table 1 ).
| Cross-reactivity of CTL epitopes between 9-mer and 10-mer peptides
Both the 9-mer SVL (SVLSRRLGK) and the 10-mer ASV (ASVLSRRLGK)
could induce peptide-specific CTLs in vitro (Figures 5, 6 ). Next, we investigated whether the two epitopes have some cross-reactivity with each other. As shown in Figure S1A , both ASV-induced and SVL-induced CTL positively reacted with both ASV-tet and SVLtet. These results suggested that these two epitopes have crossreactivities. Regarding peptide-specific CTL induction, 10-mer ASV might be more immunogenic than 9-mer SVL.
We also assessed cross-reactivity between 10-mer LSA (LSALPPPLHK) and a 9-mer SAL (SALPPPLHK). LSA-induced CTL reacted with LSA-tet but not with SAL-tet. In addition, LSA could not induce LSA-tet-positive cells (Figures 5B, S1B) . No cross-reactivity was observed between the LSA and SAL peptides. The specific pMHC-TCR interaction suggests that 10-mer LSA is the optimallength CTL epitope.
By comparison of ASV-induced CTL with LSA and QVT-induced CTL, a difference was observed in CTL precursor frequency ( Table 1) . As shown in Figures 3 and 4 , only one tetramer-positive well was detected in a 96-well plate after MLPC using LSA and QVT. These results suggested low frequencies of peptide-specific CTL precursors in peripheral blood CD8 + T cells (3 × 10 −7 ). It is well known that the frequency of tumor-associated antigen (TAA)-specific CTL precursors is below 10 −6 in healthy peripheral blood. 6, 12 To our surprise, tetramer-positive CTL after MLPC using ASV peptide were detected in all columns of Donor A, Donor B and Donor C ( Figure 5 ). It is very likely that the probability of such an occurrence is driven by T-cell cross-reactivity as a result of amino acid sequence homology between ASV and other peptides derived from some foreign antigen. Based on these considerations, we carried out a protein-protein BLAST search for short exact matches on the NCBI website (http://www.ncbi.nlm.nih.gov/BLAST/) to retrieve homology data across species. As a result, we identified a homologous peptide that has one amino acid substitution at position 6 of the 10-mer ASV epitope (ASVLSRRLGK→ASVLSQRLGK). The ASV (R6Q) peptide is derived from the ROK family protein (Pfam 00480), which is a large family of bacterial polypeptides that includes many functionally uncharacterized gene products. 14 We carried out MLPC to investigate whether the two epitopes have cross-reactivity with each other. As shown in Figure S1C , both PBF-ASV and ROS-ASV (R6Q) peptides could induce CTL that positively reacted with ASV-tet. ASV (R6Q)-tet could also react with CTL induced by both peptides, but the reactivity was lower than that of ASV-tet. These results suggest that PBF-ASV and ROS-ASV (R6Q) might share the TCR repertoire with different pMHC-TCR affinities.
| Cytokine production capacity of peptide-induced CTL
Next, we carried out intracellular IFN-γ staining to evaluate the functionality of CTL induced by QVT, LSA, ASV or SVL epitope.
Resultant CTL after MLPC were restimulated with a cognate peptide at various concentrations in the presence of brefeldin A. As a result, both QVT and LSA efficiently induced IFN-γ production in a dose-dependent way ( Figure 7A,B) . In contrast, although CTL were detectable with MHC-tetramers, ASV and SVL could not induce specific IFN-γ production ( Figure 7C,D) . Peptide-specific tumor necrosis factor (TNF)-α production and expression of CD107a and CD137 were not observed ( Figures S2, S3 , Data S1). These results indicated that functional CTL could be induced by QVT and LSA but not by ASV and SVL. 
| D ISCUSS I ON
We previously reported three PBF-derived CTL epitopes restricted by HLA-B55, HLA-A24 or HLA-A2. [5] [6] [7] In the present study, we first identified two PBF-derived HLA-A We also characterized two other PBF-derived CTL epitopes, ASV and SVL, that have the ability to induce tetramer-positive T cells.
However, such CTL could not produce specific IFN-γ and TNF-α.
Because the generation of specific CTL was done with peptides but without additional costimulators and antigen-presenting cells in our experiments, it is possible that CTL induced by these specific pep- 
22-27
Furthermore, we identified a homologous peptide, ASV (R6Q), derived from a microbial ROS family protein. As shown in Figure S1 , both ASV and ROS-ASV (R6Q) could induce peptidespecific T-cell responses with similar frequencies, suggesting that ASV and ROS-ASV (R6Q) share the same TCR repertoire. Crossreactivity of T cells between self-antigens and microbial antigens has previously been described for both CD4 + and CD8 + T cells. Web-based in silico prediction has been widely used as a starting peptide collection for T-cell epitope discovery. 29 suffer from high rates of false-negative and false-positive results. In
the present study, we developed an in vitro folding system to directly determine a peptide-MHC complex using HPLC. HPLC is more accurate and reliable for the determination of pMHC levels whereas ELISA shows more variability and less accurate estimation of the levels. Use of the in vitro folding assay might be a useful strategy for T-cell epitope discovery.
In the development of peptide-based immunotherapy strategies, it is becoming increasingly important to cover a large population identified until now. We focused on the HLA-A11 allele because of its wide expression in many ethnic populations. Therefore, the newly F I G U R E 6 MHC-tetramer reactivity with CTL after mixed lymphocyte peptide culture using a mixture of SVL, KVL and SSL peptides. PBMC from three healthy subjects (Donors A, B and C) were stimulated with a mixture of peptides (SVL, KVL and SSL). After peptide mixture stimulation, cells of columns 1-12 were stained with mixed tetramers (SVL-tet, KVL-tet and SSL-tet). Tetramer-positive cells were detected in almost all columns of Donor A, Donor B and Donor C (A). Column 6 of Donor A, column 11 of Donor B and column 6 of Donor C were selected for an assay with each tetramer, and a positive cell population was confirmed only when staining with SVL-tet (B). Frequency of tetramer-positive cells is shown as the percentage of total CD8 + T cells identified epitopes will benefit broad-spectrum approaches for the development of PBF-targeted immunotherapies.
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